Peptides News and Research

RSS

Decreased removal of toxic peptides causes onset of Alzheimer's disease

Jens Pahnke and his team at the University of Oslo has recently published results in the prestigious scientific journal 'BRAIN' showing that decreased removal of toxic peptides in the brain causes the onset and first clinical signs of Alzheimer's disease, rather than overproduction as has previously been assumed. This information can now be used to target specific genes to enhance their function in the brain of elderly or people at risk.

22 May 2015

Breakthrough in fight against rare kidney disease - Membranous Nephropathy

Scientists at The University of Manchester and Central Manchester University Hospitals NHS Foundation Trust have made a significant breakthrough in the fight against Membranous Nephropathy (MN) - a rare kidney disease which can lead to kidney failure.

22 May 2015

Changes in cell membrane play pivotal role in how HCV replicates

New research from the University of Southampton has identified how changes in the cell membrane play a pivotal role in how the Hepatitis C virus replicates.

20 May 2015

Meta-analysis supports ambrisentan efficacy

A meta-analysis supports the efficacy of ambrisentan in patients with pulmonary arterial hypertension.

15 May 2015

Case Western Reserve researchers find potential game-changer for triple-negative breast cancer

Researchers at Case Western Reserve University combined finely crafted nanoparticles with one of nature's potent disrupters to prevent the spread of triple-negative breast cancer in mouse models.

13 May 2015

Repetitive head injuries may accelerate aging process, increase dementia risk

Repetitive head injuries that occur during contact sports and military service may accelerate the aging process by increasing the build-up of beta-amyloid in the brain, leading to worse disease and an increased likelihood of developing dementia. In particular, boxers fared the worst among athletes and military veterans with a history of head injuries.

13 May 2015

Green tea compound, voluntary exercise slow Alzheimer's disease progression in mice

According to the National Institutes of Health, Alzheimer's disease (AD) may affect as many as 5.5 million Americans. Scientists currently are seeking treatments and therapies found in common foods that will help stave off the disease or prevent it completely.

5 May 2015

Promising compound blocks production of beta amyloid peptides in Alzheimer's mouse model

Offering a potential early intervention for Alzheimer's disease (AD), researchers at University of California, San Diego School of Medicine and Cenna Biosciences, Inc. have identified compounds that block the production of beta amyloid peptides in mice.

30 Apr 2015

Yale researchers successfully correct gene mutation that causes cystic fibrosis

Yale researchers successfully corrected the most common mutation in the gene that causes cystic fibrosis, a lethal genetic disorder. The study was published April 27 in Nature Communications.

28 Apr 2015

Glide's solid dose formulation of teriparatide achieves successful results in pre-clinical study

Glide Technologies, the development company focused on solid dose formulations of therapeutics and vaccines and non-invasive diagnostics, today announced that its novel solid dose formulation of teriparatide (parathyroid hormone) achieved successful results in a pre-clinical proof-of-concept study comparing it with the currently marketed liquid product (Forteo/Forsteo).

24 Apr 2015

Glide's solid dose formulation of teriparatide achieves successful results in pre-clinical study

24 Apr 2015

Diabetes drug liraglutide could prove to be a new treatment option for NASH

A drug approved to treat type 2 diabetes could prove to be a powerful new treatment option for non-alcoholic steatohepatitis (NASH), according to research presented today at The International Liver Congress 2015. Results from a randomised controlled trial showed liraglutide met the primary endpoint of histological clearance of NASH, and a reduction in the progression of fibrosis.

23 Apr 2015

Novel treatment strategy targets treatment-resistant CML

Researchers have shown that the coiled-coil mimetic CCmut3 can inhibit cell growth and promote apoptosis in cell lines expressing BCR–ABL1, including those resistant to tyrosine kinase inhibitors.

20 Apr 2015

New set of molecules could carry medicines into cells

Just as a scientist dressed in a lab coat and goggles might get stuck behind the velvet rope at a trendy bar, many otherwise good drugs can't get inside cells if they don't look the part. In a report published this week in ACS Central Science, researchers report a new set of molecules that could ferry medicines into cells by taking on the right charge and shape, easily sliding past lipid membranes.

16 Apr 2015

SELLAS inks exclusive global collaboration, license agreement with TrojanTec

SELLAS Life Sciences Group, a Swiss based, development-stage biopharmaceutical company with its main focus in developing innovative products for the treatment of various indications in Oncology and the Central Nervous System, today announced that it has signed an exclusive global collaboration and license agreement with TrojanTec Ltd, a UK-based Discovery Research and Development Company affiliated with Imperial College London, UK, for the development, marketing and commercialization of the innovative and proprietary TR-1 cancer therapeutic technology and drug.

15 Apr 2015

JPK reports on the use of the NanoWizard® 3 AFM system at the Hebrew University of Jerusalem

JPK Instruments, a world-leading manufacturer of nanoanalytic instrumentation for research in life sciences and soft matter, reports on the use of their NanoWizard® AFM system in the Institute of Chemistry of the Hebrew University of Jerusalem...

From Bruker BioAFM 14 Apr 2015

Research opens door to potential drug target for deadly Ebola virus

Opening the door to potential treatments for the deadly Ebola virus, scientists have found that a protein made by the virus plays a role similar to that of a coat-check attendant.

9 Apr 2015

UAB scientists create alternative to the use of viruses in gene therapy

A team of scientists from the Institute for Biotechnology and Biomedicine at the UAB has produced an alternative to the use of viruses in gene therapy. The researchers synthesised nanoparticles which act as artificial viruses, capable of surrounding DNA fragments and releasing them as therapeutic agents, with no biological risk, into the interior of the cells.

9 Apr 2015

Plymouth researchers receive grant to develop effective therapy for Huntington's disease

Huntington's disease is an hereditary disorder of the nervous system caused by a faulty gene on chromosome four. The faulty gene leads to nerve damage in the area of the brain resulting in gradual physical, mental and emotional changes. Those born to a parent with Huntington's disease have a 50:50 chance of developing it, and there is currently no cure.

9 Apr 2015

Rhythm, Actavis announce initiation of relamorelin Phase 2b trial for treatment of diabetic gastroparesis

Rhythm, a biopharmaceutical company, and Actavis plc, a leading global pharmaceutical company, announced today the initiation of a Phase 2b clinical trial assessing the efficacy and safety of relamorelin (RM-131), Rhythm's ghrelin agonist, for the treatment of gastroparesis in patients with type 1 and type 2 diabetes.

8 Apr 2015

Peptides News and Research

Decreased removal of toxic peptides causes onset of Alzheimer's disease

Breakthrough in fight against rare kidney disease - Membranous Nephropathy

Changes in cell membrane play pivotal role in how HCV replicates

Meta-analysis supports ambrisentan efficacy

Case Western Reserve researchers find potential game-changer for triple-negative breast cancer

Repetitive head injuries may accelerate aging process, increase dementia risk

Green tea compound, voluntary exercise slow Alzheimer's disease progression in mice

Promising compound blocks production of beta amyloid peptides in Alzheimer's mouse model

Yale researchers successfully correct gene mutation that causes cystic fibrosis

Glide's solid dose formulation of teriparatide achieves successful results in pre-clinical study

Glide's solid dose formulation of teriparatide achieves successful results in pre-clinical study

Diabetes drug liraglutide could prove to be a new treatment option for NASH

Novel treatment strategy targets treatment-resistant CML

New set of molecules could carry medicines into cells

SELLAS inks exclusive global collaboration, license agreement with TrojanTec

JPK reports on the use of the NanoWizard® 3 AFM system at the Hebrew University of Jerusalem

Research opens door to potential drug target for deadly Ebola virus

UAB scientists create alternative to the use of viruses in gene therapy

Plymouth researchers receive grant to develop effective therapy for Huntington's disease

Rhythm, Actavis announce initiation of relamorelin Phase 2b trial for treatment of diabetic gastroparesis

Editorial Focus eBook - Peptides and Oligonucleotides (2nd edition) eBook

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News